2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition
CA 2005205 A1 · Owner: Erion, Mark D. · Inventors: Erion, Mark D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
4-17360/1+2/+/CGC 1385, 2',3'-DIDEOXYPURINE NUCLEOSIDE/PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR COMBINATION THERAPY AND COMPOSITION Abstract of the Disclosure, Combination therapy of 2',3'-dideoxypurine nucleoside and purine nucleoside phosphorylase inhibitor is disclosed for the treatment of human immunodeficiency virus (AIDS) and other retrovirus infections for slowing the in-vivo decomposition of2',3'-dideoxypurine nucleoside and for enhancing the effectiveness of 2',3'-dideoxypurine nucleoside. Compositions used in these therapy methods are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 12, 1989. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 12, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 12, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.